Insider · CIK 0001503593

Cavanagh William

Reports to the SEC for 1 company · RICHLAND, WA

sec.gov

Transactions

Companies

Filings

CIK

0001503593

Forms 4 and 5

Insider transactions

25 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-07-21	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+475K sh	—	—	1,493,846
2021-07-01	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+320K sh	—	—	1,025,506
2020-10-22	CATXPerspective Therapeutics, Inc. · Warrant (right to buy)P Purchase	Chief R&D Officer	PPurchase	+3,846 sh	—	—	705,506
2020-10-22	CATXPerspective Therapeutics, Inc.P Purchase	Chief R&D Officer	PPurchase	+7,692 sh	$0.52	+$3,999.84	27,692
2020-06-23	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+150K sh	—	—	701,660
2019-11-15	CATXPerspective Therapeutics, Inc.P Purchase	Chief R&D Officer	PPurchase	+10K sh	$0.39	+$3,900	20,000
2019-06-18	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+150K sh	—	—	551,660
2018-11-16	CATXPerspective Therapeutics, Inc.P Purchase	Chief R&D Officer	PPurchase	+10K sh	$0.40	+$4,000	10,000
2018-06-13	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+150K sh	—	—	401,660
2017-06-27	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief R&D Officer	AAward	+225K sh	—	—	0
2017-06-15	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)D Disposition to Issuer	Chief R&D Officer	DDisposition to Issuer	−20K sh	—	—	0
2017-06-15	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)D Disposition to Issuer	Chief R&D Officer	DDisposition to Issuer	−125K sh	—	—	0
2016-06-21	CATXPerspective Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief R&D Officer	AAward	+125K sh	—	—	125,000
2015-06-18	CATXPerspective Therapeutics, Inc. · Stock optionsA Award	Chief R&D Officer	AAward	+20K sh	—	—	20,000
2015-04-02	CATXPerspective Therapeutics, Inc. · Stock Options (right to buy)M Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	−13.3K sh	—	—	6,660
2015-04-02	CATXPerspective Therapeutics, Inc.M Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	+13.3K sh	$0.98	+$13.1K	13,340
2015-04-02	CATXPerspective Therapeutics, Inc.S Sale	Chief R&D Officer	SSale	−13.3K sh	$1.53	−$20.4K	0
2014-06-17	CATXPerspective Therapeutics, Inc. · Stock OptionsA Award	Chief R&D Officer	AAward	+20K sh	—	—	20,000
2014-05-27	CATXPerspective Therapeutics, Inc. · Stock OptionsM Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	−15K sh	—	—	0
2014-05-27	CATXPerspective Therapeutics, Inc.M Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	+15.6K sh	$0.99	+$15.4K	30,571
2014-05-27	CATXPerspective Therapeutics, Inc.M Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	+15K sh	$0.84	+$12.6K	15,000
2014-05-27	CATXPerspective Therapeutics, Inc. · Stock OptionsM Exercise/Conversion	Chief R&D Officer	MExercise/Conversion	−15.6K sh	—	—	7,774
2014-05-27	CATXPerspective Therapeutics, Inc.S Sale	Chief R&D Officer	SSale	−30.6K sh	$2.22	−$67.9K	0
2012-06-27	CATXPerspective Therapeutics, Inc. · Stock OptionsA Award	Chief R&D Officer	AAward	+20K sh	—	—	0
2011-06-07	CATXPerspective Therapeutics, Inc. · Stock OptionsA Award	Chief R&D Officer	AAward	+35K sh	—	—	35,000

Recent filings

Accepted (ET)
Aug 14
Cavanagh William0001437749-22-018298
SEC(opens sec.gov)
Jul 64
Cavanagh William0001437749-21-016459
SEC(opens sec.gov)
Oct 284
Cavanagh William0001437749-20-021855
SEC(opens sec.gov)
Jun 254
Cavanagh William0001437749-20-013874
SEC(opens sec.gov)
Nov 194
Cavanagh William0001437749-19-023220
SEC(opens sec.gov)
Jun 274
Cavanagh William0001437749-19-012916
SEC(opens sec.gov)
Nov 164
Cavanagh William0001437749-18-021027
SEC(opens sec.gov)
Jun 194
Cavanagh William0001437749-18-012091
SEC(opens sec.gov)
Jun 294
IsoRay, Inc.0001642247-17-000011
SEC(opens sec.gov)
Jun 234
IsoRay, Inc.0001503593-16-000003
SEC(opens sec.gov)
Jun 224
IsoRay, Inc.0001503593-15-000002
SEC(opens sec.gov)
Apr 284
IsoRay, Inc.0001503593-15-000001
SEC(opens sec.gov)
Jul 104
IsoRay, Inc.0001503593-14-000004
SEC(opens sec.gov)
Jul 24/A
IsoRay, Inc.0001503593-14-000002
SEC(opens sec.gov)

Companies

Perspective Therapeutics, Inc.Chief R&D OfficerCATX

Address

350 HILLS STREET SUITE 106

RICHLAND, WA, 99354